In the last trading session, 1.02 million shares of the Inovio Pharmaceuticals Inc (NASDAQ:INO) were traded, and its beta was 1.81. Most recently the company’s share price was $1.81, and it changed around -$0.07 or -3.72% from the last close, which brings the market valuation of the company to $66.37M. INO currently trades at a discount to its 52-week high of $14.75, offering almost -714.92% off that amount. The share price’s 52-week low was $1.74, which indicates that the current value has risen by an impressive 3.87% since then. We note from Inovio Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 0.83 million shares, with the 3-month average coming to 874.26K.
Inovio Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 3 recommended INO as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Inovio Pharmaceuticals Inc is expected to report earnings per share of -0.74 for the current quarter.
Inovio Pharmaceuticals Inc (NASDAQ:INO) trade information
Instantly INO has showed a red trend with a performance of -3.72% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.1250 on recent trading dayincreased the stock’s daily price by 14.82%. The company’s shares are currently down -1.09% year-to-date, but still down -13.81% over the last five days. On the other hand, Inovio Pharmaceuticals Inc (NASDAQ:INO) is -10.40% down in the 30-day period. We can see from the shorts that 5.52 million shares have been sold at a short interest cover period of 7.86 day(s).
The consensus price target as assigned by Wall Street analysts is $20, which translates to bulls needing to increase their stock price by 90.95% from its current value. Analyst projections state that INO is forecast to be at a low of $8 and a high of $40.
Inovio Pharmaceuticals Inc (INO) estimates and forecasts
The year-over-year growth rate is expected to be -81.63%, down from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 10k in revenue for the current quarter. 5 analysts expect Inovio Pharmaceuticals Inc to make 10k in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at -90.08%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 22.92%. Inovio Pharmaceuticals Inc earnings are expected to increase by 34.50% in 2025, but the outlook is positive 29.75% per year for the next five years.
INO Dividends
Inovio Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2025-Mar-17.
Inovio Pharmaceuticals Inc (NASDAQ:INO)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.68% of Inovio Pharmaceuticals Inc shares, and 36.60% of them are in the hands of institutional investors. The stock currently has a share float of 36.85%. Inovio Pharmaceuticals Inc stock is held by 142.0 institutions, with DEEP TRACK CAPITAL, LP being the largest institutional investor. By 2024-06-30, it held 7.5988% of the shares, which is about 2.07 million shares worth $16.7 million.
BLACKROCK INC., with 6.2741% or 1.71 million shares worth $13.79 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 818.82 shares worth $1.48 million, making up 2.23% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 714.87 shares worth around $1.29 million, which represents about 1.95% of the total shares outstanding.
